WO2022184659 - ANTIBODY DOMAINS & MULTIMERS
National phase entry is expected:
Publication Number
WO/2022/184659
Publication Date
09.09.2022
International Application No.
PCT/EP2022/055020
International Filing Date
28.02.2022
Title **
[English]
ANTIBODY DOMAINS & MULTIMERS
[French]
DOMAINES D'ANTICORPS ET MULTIMÈRES
Applicants **
QUADRUCEPT BIO LIMITED
Inventors
ALI, Hanif
Priority Data
2102896.4
01.03.2021
GB
2103153.9
06.03.2021
GB
PCT/EP2021/056576
15.03.2021
EP
2201282.7
01.02.2022
GB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5830 | |
| EPO | Filing, Examination, Granting | 34377 | |
| Japan | Filing, Examination, Granting | 3267 | |
| South Korea | Filing, Examination, Granting | 4556 | |
| USA | Filing, Examination, Granting | 18390 |
Total:
66,420
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention relates to novel antibody variable domains that bind to coronavirus virus spike (eg, SARS-CoV-2 spike, SARS-CoV-1 spike or beta-coronavirus spike). Also provided are multimers, such as multimers comprising 4 copies of such a variable domain. Advantageously and surprisingly, such multimers are capable of neutralising divergent strains of SARS-Cov-2 such as delta and omicron.[French]
L'invention concerne de nouveaux domaines variables d'anticorps qui se lient à la spicule du virus de coronavirus (par exemple, spicule du SARS-CoV-2, spicule du SARS-CoV-1 ou spicule du bêta-coronavirus). L'invention concerne également des multimères, tels que des multimères comprenant 4 copies d'un tel domaine variable. De manière avantageuse et surprenante, de tels multimères sont capables de neutraliser des souches divergentes du SARS-CoV-2 telles que delta et omicron.